Cargando…
Antibody response to COVID-19 vaccines among workers with a wide range of exposure to per- and polyfluoroalkyl substances
Per- and polyfluoroalkyl substances (PFAS) are a broad class of synthetic chemicals; some are present in most humans in developed countries. Several studies have shown associations between certain PFAS, such as perfluorooctanoic acid (PFOA) and perfluorooctane sulfonic acid (PFOS), and reduced antib...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489981/ https://www.ncbi.nlm.nih.gov/pubmed/36183490 http://dx.doi.org/10.1016/j.envint.2022.107537 |
_version_ | 1784792989378281472 |
---|---|
author | Porter, Anna K. Kleinschmidt, Sarah E. Andres, Kara L. Reusch, Courtney N. Krisko, Ryan M. Taiwo, Oyebode A. Olsen, Geary W. Longnecker, Matthew P. |
author_facet | Porter, Anna K. Kleinschmidt, Sarah E. Andres, Kara L. Reusch, Courtney N. Krisko, Ryan M. Taiwo, Oyebode A. Olsen, Geary W. Longnecker, Matthew P. |
author_sort | Porter, Anna K. |
collection | PubMed |
description | Per- and polyfluoroalkyl substances (PFAS) are a broad class of synthetic chemicals; some are present in most humans in developed countries. Several studies have shown associations between certain PFAS, such as perfluorooctanoic acid (PFOA) and perfluorooctane sulfonic acid (PFOS), and reduced antibody concentration after vaccination against diseases such as Tetanus. Recent studies have reported associations between COVID-19 occurrence and exposure to certain types of PFAS. However, studies of antibody concentration after COVID-19 vaccination in relation to PFAS serum concentrations have not been reported. We examined COVID-19 antibody responses to vaccines and PFAS serum concentrations among employees and retirees from two 3M facilities, one of which historically manufactured PFOS, PFOA, and perfluorohexane sulfonic acid (PFHxS). Participants completed enrollment and follow-up study visits in the Spring of 2021, when vaccines were widely available. In total 415 participants with 757 observations were included in repeated measures analyses. Log-transformed concentrations of anti-spike IgG and neutralizing antibodies were modeled in relation to concentration of PFAS at enrollment after adjusting for antigenic stimulus group (9 groups determined by COVID-19 history and number and type of vaccination) and other variables. The fully adjusted IgG concentration was 3.45 percent lower (95% CI −7.03, 0.26) per 14.5 ng/mL (interquartile range) increase in PFOS; results for neutralizing antibody and PFOS were similar. For PFOA, PFHxS, and perfluorononanoic acid (PFNA), the results were comparable to those for PFOS, though of smaller magnitude. In our study data, the fully adjusted coefficients relating concentration of vaccine-induced antibodies to COVID-19 and interquartile range difference in serum concentration of PFOS, PFOA, PFHxS, and PFNA were inverse but small with confidence intervals that included zero. Our analysis showed that the coefficient for the four PFAS examined in detail was considerably affected by adjustment for antigenic stimulus group. |
format | Online Article Text |
id | pubmed-9489981 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Authors. Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94899812022-09-21 Antibody response to COVID-19 vaccines among workers with a wide range of exposure to per- and polyfluoroalkyl substances Porter, Anna K. Kleinschmidt, Sarah E. Andres, Kara L. Reusch, Courtney N. Krisko, Ryan M. Taiwo, Oyebode A. Olsen, Geary W. Longnecker, Matthew P. Environ Int Full Length Article Per- and polyfluoroalkyl substances (PFAS) are a broad class of synthetic chemicals; some are present in most humans in developed countries. Several studies have shown associations between certain PFAS, such as perfluorooctanoic acid (PFOA) and perfluorooctane sulfonic acid (PFOS), and reduced antibody concentration after vaccination against diseases such as Tetanus. Recent studies have reported associations between COVID-19 occurrence and exposure to certain types of PFAS. However, studies of antibody concentration after COVID-19 vaccination in relation to PFAS serum concentrations have not been reported. We examined COVID-19 antibody responses to vaccines and PFAS serum concentrations among employees and retirees from two 3M facilities, one of which historically manufactured PFOS, PFOA, and perfluorohexane sulfonic acid (PFHxS). Participants completed enrollment and follow-up study visits in the Spring of 2021, when vaccines were widely available. In total 415 participants with 757 observations were included in repeated measures analyses. Log-transformed concentrations of anti-spike IgG and neutralizing antibodies were modeled in relation to concentration of PFAS at enrollment after adjusting for antigenic stimulus group (9 groups determined by COVID-19 history and number and type of vaccination) and other variables. The fully adjusted IgG concentration was 3.45 percent lower (95% CI −7.03, 0.26) per 14.5 ng/mL (interquartile range) increase in PFOS; results for neutralizing antibody and PFOS were similar. For PFOA, PFHxS, and perfluorononanoic acid (PFNA), the results were comparable to those for PFOS, though of smaller magnitude. In our study data, the fully adjusted coefficients relating concentration of vaccine-induced antibodies to COVID-19 and interquartile range difference in serum concentration of PFOS, PFOA, PFHxS, and PFNA were inverse but small with confidence intervals that included zero. Our analysis showed that the coefficient for the four PFAS examined in detail was considerably affected by adjustment for antigenic stimulus group. The Authors. Published by Elsevier Ltd. 2022-11 2022-09-21 /pmc/articles/PMC9489981/ /pubmed/36183490 http://dx.doi.org/10.1016/j.envint.2022.107537 Text en © 2022 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Full Length Article Porter, Anna K. Kleinschmidt, Sarah E. Andres, Kara L. Reusch, Courtney N. Krisko, Ryan M. Taiwo, Oyebode A. Olsen, Geary W. Longnecker, Matthew P. Antibody response to COVID-19 vaccines among workers with a wide range of exposure to per- and polyfluoroalkyl substances |
title | Antibody response to COVID-19 vaccines among workers with a wide range of exposure to per- and polyfluoroalkyl substances |
title_full | Antibody response to COVID-19 vaccines among workers with a wide range of exposure to per- and polyfluoroalkyl substances |
title_fullStr | Antibody response to COVID-19 vaccines among workers with a wide range of exposure to per- and polyfluoroalkyl substances |
title_full_unstemmed | Antibody response to COVID-19 vaccines among workers with a wide range of exposure to per- and polyfluoroalkyl substances |
title_short | Antibody response to COVID-19 vaccines among workers with a wide range of exposure to per- and polyfluoroalkyl substances |
title_sort | antibody response to covid-19 vaccines among workers with a wide range of exposure to per- and polyfluoroalkyl substances |
topic | Full Length Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489981/ https://www.ncbi.nlm.nih.gov/pubmed/36183490 http://dx.doi.org/10.1016/j.envint.2022.107537 |
work_keys_str_mv | AT porterannak antibodyresponsetocovid19vaccinesamongworkerswithawiderangeofexposuretoperandpolyfluoroalkylsubstances AT kleinschmidtsarahe antibodyresponsetocovid19vaccinesamongworkerswithawiderangeofexposuretoperandpolyfluoroalkylsubstances AT andreskaral antibodyresponsetocovid19vaccinesamongworkerswithawiderangeofexposuretoperandpolyfluoroalkylsubstances AT reuschcourtneyn antibodyresponsetocovid19vaccinesamongworkerswithawiderangeofexposuretoperandpolyfluoroalkylsubstances AT kriskoryanm antibodyresponsetocovid19vaccinesamongworkerswithawiderangeofexposuretoperandpolyfluoroalkylsubstances AT taiwooyebodea antibodyresponsetocovid19vaccinesamongworkerswithawiderangeofexposuretoperandpolyfluoroalkylsubstances AT olsengearyw antibodyresponsetocovid19vaccinesamongworkerswithawiderangeofexposuretoperandpolyfluoroalkylsubstances AT longneckermatthewp antibodyresponsetocovid19vaccinesamongworkerswithawiderangeofexposuretoperandpolyfluoroalkylsubstances |